Futibatinib by Otsuka Pharmaceutical for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).

Related Keywords

Japan ,Tokyo ,Chiyoda Ku ,Futibatinib Lytgobi ,Otsuka Holdings Co Ltd ,Globaldata Pharmaceutical Intelligence Center ,Otsuka Pharmaceutical ,Esophageal Squamous Cell Carcinoma ,Phase Transition Success Rate Model ,Pharmaceutical Intelligence ,